Dimensional Fund Advisors LP Acquires 121,305 Shares of Repligen Co. (NASDAQ:RGEN)

Dimensional Fund Advisors LP increased its holdings in Repligen Co. (NASDAQ:RGEN) by 39.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 429,524 shares of the biotechnology company’s stock after purchasing an additional 121,305 shares during the period. Dimensional Fund Advisors LP owned approximately 0.77% of Repligen worth $54,149,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Envestnet Asset Management Inc. boosted its holdings in Repligen by 0.7% in the second quarter. Envestnet Asset Management Inc. now owns 108,741 shares of the biotechnology company’s stock worth $13,708,000 after purchasing an additional 741 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in Repligen by 16.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 19,574 shares of the biotechnology company’s stock worth $2,467,000 after purchasing an additional 2,783 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 89 shares in the last quarter. Johnson Investment Counsel Inc. boosted its holdings in Repligen by 2.8% in the second quarter. Johnson Investment Counsel Inc. now owns 15,406 shares of the biotechnology company’s stock worth $1,942,000 after purchasing an additional 425 shares in the last quarter. Finally, Forsta AP Fonden boosted its holdings in Repligen by 6.6% in the second quarter. Forsta AP Fonden now owns 12,900 shares of the biotechnology company’s stock worth $1,626,000 after purchasing an additional 800 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on RGEN shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday. Guggenheim assumed coverage on shares of Repligen in a report on Tuesday, June 18th. They set a “neutral” rating for the company. Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Finally, UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Down 0.8 %

NASDAQ RGEN opened at $145.93 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The firm has a 50-day simple moving average of $148.80 and a 200 day simple moving average of $153.71. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The stock has a market cap of $8.17 billion, a PE ratio of 583.74, a PEG ratio of 4.23 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter last year, the company earned $0.53 earnings per share. The firm’s revenue was down 3.2% on a year-over-year basis. On average, research analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.